	UNAUDITED FINANCIAL				•	
						(Rs. In Lacs)
Sr.		UNAUDITED		UNAUDITED		AUDITED
No.	Particulars	Quarter	Quarter	Nine Months	Nine Months	Accounting
		ended on	ended on	ended on	ended on	Year ended on
_		31/12/2008	31/12/2007	12/31/2008	12/31/2007	31/03/2008
	Net Sales / Income from Operations	4,726.93	2,946.08	13,622.87	8,902.02	11,905.0
3	Other Income	45.54 4,772.47	70.64 3,016.72	136.87 13,759.74	223.81 9,125.83	268.0 12,173.0
4	Total Income (1+ 2) Total Expenditure	4,772.47	3,016.72	13,759.74	9,125.63	12,173.0
_	a) (Increase)/Decrease in Stock in Trade	(20.73)	(81.99)	(1,026.38)	(34.33)	226.
	b) Consumption of Raw Materials	2,484.69	2,365.91	8,399.96	7,067.61	6,118.
	c) Purchase of Traded goods	2,151.06	-	4,517.97	-	3,069.
	d) Employee Cost	113.79	101.57	362.50	277.51	384.
	e) Depreciation	52.78	49.58	159.09	142.32	183.
	f) Other Expenditure (See Note No. 7)	790.55	273.93	1,583.89	753.44	1,013.
	g) Total	5,572.14	2,709.00	13,997.03	8,206.55	10,995.
	Profit / (Loss) from Ordinary Activities before	(799.67)	307.72	(237.29)	919.28	1,177.
	Interest Tax and Exceptional Items					
-	Interest	330.65	173.52	760.69	499.58	680.
_	Exceptional items	-	-	-	-	-
7	Profit/(Loss) from Ordinary Activities before Tax	(1,130.32)	134.20	(997.98)	419.70	497.
	Tax expenses	305.87	(28.92)	264.98	(111.72)	(109.
10	Profit / (loss) from Ordinary Activities after Tax	(824.45)	105.28	(733.00)	307.98	388.
10	Extraordinary Items Net Profit / (Net loss) for the period (9-10)	(824.45)	105.28	(733.00)	307.98	388.
12	Paid-up equity Share capital	1,050.06	1.050.06	1,050.06	1,050.06	1,050
	(Face value Rs. 10/-)	1,000.00	1,000.00	1,000.00	1,000.00	1,000.
13	Reserves excluding revaluation	1				7,695
_	reserves (As per Balance Sheet of previous					.,500
	accounting year)					
14	Earning per Equity Shares (EPS)					
	Basic	(7.85)	1.00	(6.98)	2.93	3.
	Diluted	(7.85)	1.00	(6.98)	2.93	4.
15	Public shareholding					
	- Number of Shares	5,636,479.00	5,844,000.00	5,636,479.00	5,844,000.00	5,744,000.
	- Percentage of Shareholding	54.70	55.65	54.70	55.65	54.
	SEGMENTWISE REVENUE, RESULTS AND O	CAPITAL EMPLOYI	ED			(Rs. In Lacs)
		UNAL	JDITED			AUDITED
	SEGMENTWISE REVENUE, RESULTS AND O	UNAL Quarter	JDITED Quarter	Nine Months	Nine Months	AUDITED Accounting
		UNAL Quarter ended on	JDITED Quarter ended on	Nine Months ended on	Nine Months ended on	AUDITED Accounting Year ended on
		UNAL Quarter	JDITED Quarter	Nine Months	Nine Months	AUDITED Accounting
	Particulars	UNAL Quarter ended on	JDITED Quarter ended on	Nine Months ended on	Nine Months ended on	AUDITED Accounting Year ended on 31/03/2008
	Particulars Segment Revenue (Net)	Quarter ended on 31/12/2008	Quarter ended on 31/12/2007	Nine Months ended on 12/31/2008	Nine Months ended on 12/31/2007	AUDITED Accounting Year ended on 31/03/2008
	Particulars Segment Revenue (Net) Pharmaceuticals	Quarter ended on 31/12/2008	Quarter ended on 31/12/2007	Nine Months ended on 12/31/2008	Nine Months ended on 12/31/2007	AUDITED Accounting Year ended on 31/03/2008
	Particulars Segment Revenue (Net) Pharmaceuticals Construction	UNAL Quarter ended on 31/12/2008	Quarter ended on 31/12/2007 3,200.28	Nine Months ended on 12/31/2008 13,622.87	Nine Months ended on 12/31/2007 9,590.54	AUDITED Accounting Year ended on 31/03/2008
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest	UNAL Quarter ended on 31/12/2008	Quarter ended on 31/12/2007 3,200.28	Nine Months ended on 12/31/2008 13,622.87	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54	AUDITED Accounting Year ended on 31/03/2008 11,905.
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals	UNAL Quarter ended on 31/12/2008	Quarter ended on 31/12/2007 3,200.28	Nine Months ended on 12/31/2008 13,622.87	Nine Months ended on 12/31/2007 9,590.54	AUDITED Accounting Year ended on 31/03/2008 11,905.
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and interest Pharmaceuticals Construction	UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 (830.86)	Quarter ended on 31/12/2007 3,200.28 - 3,200.28	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30)	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54	AUDITED Accounting Year ended on 31/03/2008 11,905.
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results	UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 (830.86)	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30)	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 834.47	AUDITED Accounting Year ended on 31/03/2008 11,905. 11,905.
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less : Interest	UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 (830.86) (830.86) (830.86)	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 499.58	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905. 1,043 1,043. 680.
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and interest Pharmaceuticals Construction Total Segment Results Less : Interest Add : Net unallocable Income	UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 (830.86) (830.86) 330.65 31.19	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52 32.04	Nine Months ended on 12/31/2008 13,622.87 13,622.87 (340.30) - (340.30) 760.69 103.01	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 - 834.47 499.58 84.80	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 680 134
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax	UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 (830.86) (830.86) (830.86)	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 499.58	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 680 134
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed	UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 (830.86) (830.86) 330.65 31.19	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52 32.04	Nine Months ended on 12/31/2008 13,622.87 13,622.87 (340.30) - (340.30) 760.69 103.01	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 - 834.47 499.58 84.80	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 680 134
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add : Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities)	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) (830.86) 330.65 31.19 (1,130.32)	Quarter ended on 31/12/2007 3,200.28 3,200.28 275.67 275.67 173.52 32.04 134.20	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98)	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 - 834.47 499.58 84.80 419.69	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 680 134 497
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals	UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 (830.86) (830.86) 330.65 31.19 (1,130.32)	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52 32.04 134.20	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98)	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 680 134 497.
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interes Pharmaceuticals Construction		UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 st (830.86)	UNAUDITED Quarter ended on ended on 31/12/2008 31/12/2007 4,726.93 3,200.28 4,726.93 3,200.28 st (830.86) 275.67	UNAUDITED UNAU	UNAUDITED UNAUDITED
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals	UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 (830.86) (830.86) 330.65 31.19 (1,130.32)	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52 32.04 134.20	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98)	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69	AUDITED Accounting Year ended on 31/03/2008 11,905.4 11,905.4 1,043.1
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less : Interest Add : Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction	UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52 32.04 134.20 4,602.62 4,124.03	Nine Months ended on 12/31/2008 13,622.87 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and interest Pharmaceuticals Construction Total Segment Results Less : Interest Add : Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed	UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 (830.86) (830.86) 330.65 31.19 (1,130.32)	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52 32.04 134.20	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98)	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38	Quarter ended on 31/12/2007 3,200.28	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06 8,037.38	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,906 11,906 1,046 680 497 5,166 3,846
1	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less : Interest Add : Net unallocable Income Total Profit before Tax Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Profit depital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed Segment Assets Less Segment Liabilities)	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) (830.86) (830.86) (1,130.32) 4,163.32 3,874.06 8,037.38 Te taken on record by the	Quarter ended on 31/12/2007 3,200.28	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06 8,037.38	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
1	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed ss:- The above results as reviewed by the Audit Committee wer The Statutory Auditors of the Company have conducted a lease of the Company have conducted a l	UNAL Quarter ended on 31/12/2008 4,726.93 - 4,726.93 (830.86) (830.86) (330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 te taken on record by the simited Review of the abo	Quarter ended on 31/12/2007 3,200.28	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06 8,037.38	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
1	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Total Capital Employed Sis:- The above results as reviewed by the Audit Committee wer The Statutory Auditors of the Company have conducted a I The details of number of investors complaints for the quarter	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 et aken on record by the cord device of the abort ended 31st Dec, 2008.	Quarter ended on 31/12/2007 3,200.28	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06 8,037.38	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
1 2 3	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed Institution Insti	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 te taken on record by the imited Review of the abor ended 31st Dec, 2008: g - 0.	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52 32.04 134.20 4,602.62 4,124.03 8,726.65 Board of Directors at it's ove results.	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06 8,037.38 meeting held on 29.01.2	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
3	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Pharmaceuticals Construction Total Segment Results Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (segment Assets Less Company have conducted a total Capital Employed The above results as reviewed by the Audit Committee were The Statutory Auditors of the Company have conducted a total Capital Incompany Incompa	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 et alken on record by the abore ended 31st Dec, 2008: g - 0. Standard 15 (Revised) on	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52 32.04 134.20 4,602.62 4,124.03 8,726.65 Board of Directors at it's ove results.	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06 8,037.38 meeting held on 29.01.2	Nine Months ended on 12/31/2007 9,590.54 - 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
1 2 3 4 5	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Construction Total Segment Results Less : Interest Add : Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed Segment Assets to Segment Liabilities) The above results as reviewed by the Audit Committee were the Statutory Auditors of the Company have conducted a Inhe details of number of investors complaints for the quarte Beginning - 0, Received - 1 , Disposed Off - 1 and Pendin Provisions' adjustments, if any, on account of Accounting Scorresponding figures of the previous year/ quarter have to	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) (830.86) (330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 te taken on record by the cimited Review of the aborer ended 31st Dec, 2008; g - 0.	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52 32.04 134.20 4,602.62 4,124.03 8,726.65 Board of Directors at it's ove results.	Nine Months ended on 12/31/2008 13,622.87 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06 8,037.38 meeting held on 29.01.2	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497 5,166 3,849
1 2 3 4 5 6	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed Sis:- The above results as reviewed by the Audit Committee wer The Statutory Auditors of the Company have conducted a I The details of number of investors complaints for the quarte Beginning - 0, Received - 1, Disposed Off - 1 and Pendin Provisions/ adjustments, if any, on account of Accounting S Corresponding figures of the previous year/ quarter have I Profitability of the company has been adversly affected due	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 et aken on record by the cimited Review of the abort ended 31st Dec, 2008: g - 0. Standard 15 (Revised) on seen regrouped / restated to high raw material cose	Quarter ended on 31/12/2007 3,200.28 3,200.28 275.67 275.67 173.52 32.04 134.20 4,602.62 4,124.03 8,726.65 Board of Directors at it's ove results.	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) - (340.30) - (997.98) 4,163.32 - 3,874.06 - 8,037.38 In meeting held on 29.01.26 at by the ICAI will be conse	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
1 2 3 4 5 6 7	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) The above results as reviewed by the Audit Committee were the Statutory Auditors of the Company have conducted at The details of number of investors complaints for the quarte Beginning - 0, Received - 1, Disposed Off - 1 and Pendin Provisions/ adjustments, if any, on account of Accounting Scorresponding figures of the previous year/ quarter have It Profitability of the company has been adversly affected due Other expenditure for the nine months includes Rs. 655.15	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 4,726.93 (830.86) (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 te taken on record by the cimited Review of the abore ended 31st Dec, 2008: g - 0. Standard 15 (Revised) on seen regrouped / restates to high raw material cost lacs towards loss on accelars.	Quarter ended on 31/12/2007 3,200.28 3,200.28 275.67 275.67 173.52 32.04 134.20 4,602.62 4,124.03 8,726.65 Board of Directors at it's ever results.	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06 8,037.38 s meeting held on 29.01.2 ed by the ICAI will be conse	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
1 2 3 4 5 6 7	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed Sis:- The above results as reviewed by the Audit Committee wer The Statutory Auditors of the Company have conducted a I The details of number of investors complaints for the quarte Beginning - 0, Received - 1, Disposed Off - 1 and Pendin Provisions/ adjustments, if any, on account of Accounting S Corresponding figures of the previous year/ quarter have I Profitability of the company has been adversly affected due	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 4,726.93 (830.86) (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 te taken on record by the cimited Review of the abore ended 31st Dec, 2008: g - 0. Standard 15 (Revised) on seen regrouped / restates to high raw material cost lacs towards loss on accelars.	Quarter ended on 31/12/2007 3,200.28 3,200.28 275.67 275.67 173.52 32.04 134.20 4,602.62 4,124.03 8,726.65 Board of Directors at it's ever results.	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06 8,037.38 s meeting held on 29.01.2 ed by the ICAI will be conse	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
1 2 3 4 5 6 7	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) The above results as reviewed by the Audit Committee were the Statutory Auditors of the Company have conducted at The details of number of investors complaints for the quarte Beginning - 0, Received - 1, Disposed Off - 1 and Pendin Provisions/ adjustments, if any, on account of Accounting Scorresponding figures of the previous year/ quarter have It Profitability of the company has been adversly affected due Other expenditure for the nine months includes Rs. 655.15	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 4,726.93 (830.86) (830.86) (330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 te taken on record by the limited Review of the abor ended 31st Dec, 2008: g - 0. Standard 15 (Revised) on opeen regrouped / restated to high raw material cos lacs towards loss on acc eferred tax provision of R	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52 32.04 134.20 4,602.62 4,124.03 8,726.65 Board of Directors at it's ever results. employee benefits issue wherever necessary. Its vis-à-vis steep declinount of foreign exchanges, 269.39 lacs has been	Nine Months ended on 12/31/2008 13,622.87 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06 8,037.38 meeting held on 29.01.2 ab y the ICAI will be conse in prices of finished goog fluctuations.	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
2 3 4 5 6 7	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) The above results as reviewed by the Audit Committee were the Statutory Auditors of the Company have conducted at The details of number of investors complaints for the quarte Beginning - 0, Received - 1, Disposed Off - 1 and Pendin Provisions/ adjustments, if any, on account of Accounting Scorresponding figures of the previous year/ quarter have It Profitability of the company has been adversly affected due Other expenditure for the nine months includes Rs. 655.15	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 et aken on record by the abort ended 31st Dec, 2008: g - 0. Standard 15 (Revised) on been regrouped / restated to high raw material cost lacs towards loss on accepterred tax provision of R	Quarter ended on 31/12/2007 3,200.28	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 - (340.30) - (340.30) - (340.30) - (997.98) - 4,163.32 - 3,874.06 - 8,037.38 - s meeting held on 29.01.2 - ed by the ICAI will be conse	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6800 134 497
1 2 3 4 5 6 7	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) The above results as reviewed by the Audit Committee were the Statutory Auditors of the Company have conducted at The details of number of investors complaints for the quarte Beginning - 0, Received - 1, Disposed Off - 1 and Pendin Provisions/ adjustments, if any, on account of Accounting Scorresponding figures of the previous year/ quarter have It Profitability of the company has been adversly affected due Other expenditure for the nine months includes Rs. 655.15	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 et aken on record by the abort ended 31st Dec, 2008: g - 0. Standard 15 (Revised) on been regrouped / restated to high raw material cost lacs towards loss on accepterred tax provision of R	Quarter ended on 31/12/2007 3,200.28 - 3,200.28 275.67 - 275.67 173.52 32.04 134.20 4,602.62 4,124.03 8,726.65 Board of Directors at it's ever results. employee benefits issue wherever necessary. Its vis-à-vis steep declinount of foreign exchanges, 269.39 lacs has been	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 - (340.30) - (340.30) - (340.30) - (997.98) - 4,163.32 - 3,874.06 - 8,037.38 - s meeting held on 29.01.2 - ed by the ICAI will be conse	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6880 134 497
1 2 3 4 5 6 7	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) The above results as reviewed by the Audit Committee were the Statutory Auditors of the Company have conducted at The details of number of investors complaints for the quarte Beginning - 0, Received - 1, Disposed Off - 1 and Pendin Provisions/ adjustments, if any, on account of Accounting Scorresponding figures of the previous year/ quarter have It Profitability of the company has been adversly affected due Other expenditure for the nine months includes Rs. 655.15	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 et aken on record by the abort ended 31st Dec, 2008: g - 0. Standard 15 (Revised) on been regrouped / restated to high raw material cost lacs towards loss on accepterred tax provision of R	Quarter ended on 31/12/2007 3,200.28	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 - (340.30) - (340.30) - (340.30) - (997.98) - 4,163.32 - 3,874.06 - 8,037.38 - s meeting held on 29.01.2 - ed by the ICAI will be conse	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6880 134 497
1 2 3 4 5 6 7	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) The above results as reviewed by the Audit Committee were the Statutory Auditors of the Company have conducted at The details of number of investors complaints for the quarte Beginning - 0, Received - 1, Disposed Off - 1 and Pendin Provisions/ adjustments, if any, on account of Accounting Scorresponding figures of the previous year/ quarter have It Profitability of the company has been adversly affected due Other expenditure for the nine months includes Rs. 655.15	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 et aken on record by the abort ended 31st Dec, 2008: g - 0. Standard 15 (Revised) on been regrouped / restated to high raw material cost lacs towards loss on accepterred tax provision of R	Quarter ended on 31/12/2007 3,200.28	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 - (340.30) - (340.30) - (340.30) - (997.98) - 4,163.32 - 3,874.06 - 8,037.38 - s meeting held on 29.01.2 - ed by the ICAI will be conse	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905. 11,905. 1,043. 680. 134. 497.
1 2 3 4 5 6 7 8	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Profit / Loss before tax and Interest Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (Segment Assets Less Segment Liabilities) The above results as reviewed by the Audit Committee were the Statutory Auditors of the Company have conducted at The details of number of investors complaints for the quarte Beginning - 0, Received - 1, Disposed Off - 1 and Pendin Provisions/ adjustments, if any, on account of Accounting Scorresponding figures of the previous year/ quarter have It Profitability of the company has been adversly affected due Other expenditure for the nine months includes Rs. 655.15	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) (830.86) (830.86) 330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 e taken on record by the imited Review of the aborder and the control of th	Quarter ended on 31/12/2007 3,200.28	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 - (340.30) - (340.30) - (340.30) - (997.98) - 4,163.32 - 3,874.06 - 8,037.38 - s meeting held on 29.01.2 - ed by the ICAI will be conse	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905. 11,905. 1,043. 6880. 134. 497.
1 2 3 4 5 6 7 8	Particulars Segment Revenue (Net) Pharmaceuticals Construction Total Revenues Segment Results Pharmaceuticals Construction Total Segment Results Pharmaceuticals Construction Total Segment Results Less: Interest Add: Net unallocable Income Total Profit before Tax Segment Capital Employed (Segment Assets Less Segment Liabilities) Pharmaceuticals Construction Total Capital Employed (segment Assets Less Segment Liabilities) The above results as reviewed by the Audit Committee were the Statutory Auditors of the Company have conducted a the details of number of investors complaints for the quarter The Statutory Auditors of the Company have conducted a the details of number of investors complaints for the quarter The Statutory Auditors of the Company have conducted a total Segment Segm	UNAL Quarter ended on 31/12/2008 4,726.93 4,726.93 (830.86) (830.86) (830.86) (330.65 31.19 (1,130.32) 4,163.32 3,874.06 8,037.38 re taken on record by the limited Review of the abore ended 31st Dec, 2008: gr on the a	Quarter ended on 31/12/2007 3,200.28 3,200.28 275.67 275.67 173.52 32.04 134.20 4,602.62 4,124.03 8,726.65 Board of Directors at it's over results. employee benefits issue I wherever necessary. Its vis-à-vis steep dering out of foreign exchanges, 269.39 lacs has been	Nine Months ended on 12/31/2008 13,622.87 - 13,622.87 (340.30) - (340.30) 760.69 103.01 (997.98) 4,163.32 3,874.06 8,037.38 meeting held on 29.01.2 ad by the ICAI will be conse in prices of finished goos fluctuations. reversed. Board of Directors of MITED	Nine Months ended on 12/31/2007 9,590.54 9,590.54 834.47 - 834.47 499.58 84.80 419.69 4,602.62 4,124.03 8,726.65	AUDITED Accounting Year ended on 31/03/2008 11,905 11,905 1,043 1,043 6880 134 497